Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{$index + 1}}. {{ watchedTerm.term }} ({{watchedTerm.accId}})
{{gene.symbol}}: {{ gene.description }}
Save what matters to you
{{ loginError }}
Sign in with your RGD account
Gene: Ankhd1 (ankyrin repeat and KH domain containing 1) Rattus norvegicus
Analyze
Symbol:
Ankhd1
Name:
ankyrin repeat and KH domain containing 1
RGD ID:
4892133
Description:
Predicted to have RNA binding activity. Predicted to be involved in innate immune response. Predicted to localize to cytoplasm. Orthologous to human ANKHD1-EIF4EBP3 (ANKHD1-EIF4EBP3 readthrough) and ANKHD1 (ankyrin repeat and KH domain containing 1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A; buspirone.
Type:
protein-coding
RefSeq Status:
VALIDATED
Also known as:
ankyrin repeat and KH domain-containing protein 1
RGD Orthologs
Alliance Genes
More Info
more info ...
More Info
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl mRatBN7.2 18 28,161,882 - 28,260,917 (+) NCBI Rnor_6.0 Ensembl 18 29,386,809 - 29,492,718 (+) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_6.0 18 29,386,906 - 29,485,611 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_5.0 18 29,093,401 - 29,190,685 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 Celera 18 27,890,421 - 27,988,091 (+) NCBI Celera Cytogenetic Map 18 p11 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Disease Annotations - ClinVar
(-)-demecolcine increases expression ISO RGD:1606539 6480464 Demecolcine results in increased expression of ANKHD1 mRNA CTD PMID:23649840 1,2-dimethylhydrazine affects expression ISO RGD:1616644 6480464 1, 2-Dimethylhydrazine affects the expression of ANKHD1 mRNA CTD PMID:22206623 1,2-dimethylhydrazine multiple interactions ISO RGD:1616644 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of ANKHD1 mRNA CTD PMID:22206623 17beta-estradiol decreases expression ISO RGD:1616644 6480464 Estradiol results in decreased expression of ANKHD1 mRNA CTD PMID:19484750 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1616644 6480464 Tetrachlorodibenzodioxin results in decreased expression of ANKHD1 mRNA CTD PMID:19770486 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1616644 6480464 [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ANKHD1 mRNA CTD PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1616644 6480464 Tetrachlorodibenzodioxin results in increased expression of ANKHD1 mRNA CTD PMID:21354282 3,4-methylenedioxymethamphetamine decreases expression ISO RGD:1616644 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of ANKHD1 mRNA CTD PMID:26251327 acrolein multiple interactions ISO RGD:1606539 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ANKHD1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ANKHD1 mRNA CTD PMID:32699268 aflatoxin B1 increases methylation ISO RGD:1606539 6480464 Aflatoxin B1 results in increased methylation of ANKHD1 intron CTD PMID:30157460 aflatoxin B2 increases methylation ISO RGD:1606539 6480464 aflatoxin B2 results in increased methylation of ANKHD1 intron CTD PMID:30157460 alpha-pinene multiple interactions ISO RGD:1606539 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ANKHD1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ANKHD1 mRNA CTD PMID:32699268 Aroclor 1254 decreases expression ISO RGD:1616644 6480464 Chlorodiphenyl 54% Chlorine results in decreased expression of ANKHD1 mRNA CTD PMID:23650126 arsenous acid multiple interactions ISO RGD:1606539 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to ANKHD1 protein] CTD PMID:26598702 benzo[a]pyrene decreases expression ISO RGD:1616644 6480464 Benzoapyrene results in decreased expression of ANKHD1 mRNA CTD PMID:19770486 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1606539 6480464 7 more ... CTD PMID:26238291 benzo[e]pyrene decreases methylation ISO RGD:1606539 6480464 benzoepyrene results in decreased methylation of ANKHD1 intron CTD PMID:30157460 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of ANKHD1 mRNA CTD PMID:27571134 buspirone increases expression EXP 6480464 Buspirone results in increased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:24136188 carbon nanotube decreases expression ISO RGD:1616644 6480464 Nanotubes, Carbon analog results in decreased expression of ANKHD1 mRNA CTD PMID:25554681 choline multiple interactions ISO RGD:1616644 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ANKHD1 gene CTD PMID:20938992 clobetasol decreases expression ISO RGD:1616644 6480464 Clobetasol results in decreased expression of ANKHD1 mRNA CTD PMID:27462272 cobalt dichloride increases expression ISO RGD:1606539 6480464 cobaltous chloride results in increased expression of ANKHD1 mRNA CTD PMID:19376846 copper(II) sulfate increases expression ISO RGD:1606539 6480464 Copper Sulfate results in increased expression of ANKHD1 mRNA CTD PMID:19549813 cyclosporin A increases expression ISO RGD:1606539 6480464 Cyclosporine results in increased expression of ANKHD1 mRNA CTD PMID:20106945 diarsenic trioxide multiple interactions ISO RGD:1606539 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to ANKHD1 protein] CTD PMID:26598702 dorsomorphin multiple interactions ISO RGD:1606539 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of ANKHD1 mRNA CTD PMID:27188386 enzyme inhibitor multiple interactions ISO RGD:1606539 6480464 [Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ANKHD1 protein CTD PMID:23301498 flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:24136188 folic acid multiple interactions ISO RGD:1616644 6480464 [1 more ... CTD PMID:20938992 , PMID:22206623 hydralazine multiple interactions ISO RGD:1606539 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA CTD PMID:17183730 isotretinoin decreases expression ISO RGD:1606539 6480464 Isotretinoin results in decreased expression of ANKHD1 mRNA CTD PMID:20436886 L-methionine multiple interactions ISO RGD:1616644 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ANKHD1 gene CTD PMID:20938992 lead(0) decreases expression ISO RGD:1606539 6480464 Lead results in decreased expression of ANKHD1 mRNA CTD PMID:19921347 lead(2+) decreases expression ISO RGD:1606539 6480464 Lead results in decreased expression of ANKHD1 mRNA CTD PMID:19921347 mercury atom increases expression ISO RGD:1606539 6480464 Mercury results in increased expression of ANKHD1 mRNA CTD PMID:16823088 mercury(0) increases expression ISO RGD:1606539 6480464 Mercury results in increased expression of ANKHD1 mRNA CTD PMID:16823088 methapyrilene decreases methylation ISO RGD:1606539 6480464 Methapyrilene results in decreased methylation of ANKHD1 intron CTD PMID:30157460 methylmercury chloride increases expression ISO RGD:1606539 6480464 methylmercuric chloride results in increased expression of ANKHD1 mRNA CTD PMID:28001369 ozone multiple interactions ISO RGD:1606539 6480464 [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ANKHD1 mRNA more ... CTD PMID:32699268 phenobarbital affects expression ISO RGD:1616644 6480464 Phenobarbital affects the expression of ANKHD1 mRNA CTD PMID:23091169 phenylmercury acetate decreases expression ISO RGD:1606539 6480464 Phenylmercuric Acetate results in decreased expression of ANKHD1 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1606539 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of ANKHD1 mRNA CTD PMID:27188386 piperonyl butoxide decreases expression EXP 6480464 Piperonyl Butoxide results in decreased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:22484513 pirinixic acid decreases expression ISO RGD:1616644 6480464 pirinixic acid results in decreased expression of ANKHD1 mRNA CTD PMID:20813756 propiconazole decreases expression ISO RGD:1616644 6480464 propiconazole results in decreased expression of ANKHD1 mRNA CTD PMID:21278054 quercetin decreases expression ISO RGD:1606539 6480464 Quercetin results in decreased expression of ANKHD1 mRNA CTD PMID:21632981 SB 431542 multiple interactions ISO RGD:1606539 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of ANKHD1 mRNA CTD PMID:27188386 sodium arsenate increases expression ISO RGD:1616644 6480464 sodium arsenate results in increased expression of ANKHD1 mRNA CTD PMID:21795629 sulforaphane increases methylation ISO RGD:1606539 6480464 sulforafan results in increased methylation of ANKHD1 gene CTD PMID:31838189 troglitazone decreases expression ISO RGD:1616644 6480464 troglitazone results in decreased expression of ANKHD1 mRNA CTD PMID:28973697 trovafloxacin increases expression EXP 6480464 trovafloxacin results in increased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:24136188 tungsten decreases expression ISO RGD:1616644 6480464 Tungsten results in decreased expression of ANKHD1 mRNA CTD PMID:30912803 valdecoxib decreases expression EXP 6480464 valdecoxib results in decreased expression of ANKHD1-EIF4EBP3 mRNA CTD PMID:24136188 valproic acid multiple interactions ISO RGD:1606539 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA CTD PMID:17183730 valproic acid increases expression ISO RGD:1606539 6480464 Valproic Acid results in increased expression of ANKHD1 mRNA CTD PMID:19101580 vincristine increases expression ISO RGD:1606539 6480464 Vincristine results in increased expression of ANKHD1 mRNA CTD PMID:23649840
Molecular Function
protein binding IPI UniProtKB:B2GV38 more ... 11344934 PMID:27191843 UniProt protein binding enables ISO RGD:1606539 , UniProtKB:Q8IWZ3-1 1624291 UniProtKB:Q9NRI5 , PMID:12812986 RGD PMID:12812986 protein binding enables ISO RGD:1606539 , UniProtKB:Q8IWZ3-2 1624291 UniProtKB:P23560-2 more ... RGD PMID:32814053 protein binding enables ISO RGD:1606539 , UniProtKB:Q8IWZ3-3 1624291 UniProtKB:P08574 more ... RGD PMID:32814053 protein binding enables ISO RGD:1606539 , UniProtKB:A0A0A0MQZ8 1624291 UniProtKB:Q13643 , PMID:27107012 RGD PMID:27107012 protein binding enables ISO RGD:1606539 1624291 UniProtKB:O00221 more ... RGD PMID:14743216 more ... protein binding ISO RGD:1606539 1624291 UniProtKB:O00221 more ... RGD PMID:14743216 more ... protein binding enables IPI UniProtKB:B2GV38 more ... 11344934 PMID:27191843 UniProt protein binding ISO RGD:1606539 , UniProtKB:Q8IWZ3-2 1624291 UniProtKB:P23560-2 more ... RGD PMID:32814053 protein binding ISO RGD:1606539 , UniProtKB:Q8IWZ3-3 1624291 UniProtKB:P08574 more ... RGD PMID:32814053 protein binding ISO RGD:1606539 , UniProtKB:A0A0A0MQZ8 1624291 UniProtKB:Q13643 , PMID:27107012 RGD PMID:27107012 protein binding ISO RGD:1606539 , UniProtKB:Q8IWZ3-1 1624291 UniProtKB:Q9NRI5 , PMID:12812986 RGD PMID:12812986 RNA binding IEA InterPro:IPR004088 , InterPro:IPR036612 1600115 GO_REF:0000002 InterPro GO_REF:0000002 RNA binding enables IEA InterPro:IPR004088 , InterPro:IPR036612 1600115 GO_REF:0000002 InterPro GO_REF:0000002
References
Additional References at PubMed
Genomics
QTLs in Region (Rnor_6.0)
61388 Bp2 Blood pressure QTL 2 3.23 arterial blood pressure trait (VT:2000000) diastolic blood pressure (CMO:0000005) 18 1 35097280 Rat 2300180 Bmd67 Bone mineral density QTL 67 4.8 0.0001 femur mineral mass (VT:0010011) bone mineral density (CMO:0001226) 18 1 38195967 Rat 2293661 Bss50 Bone structure and strength QTL 50 4.64 0.0003 lumbar vertebra size trait (VT:0010518) lumbar vertebra trabecular cross-sectional area (CMO:0001692) 18 1 38195967 Rat 9589153 Insul31 Insulin level QTL 31 7.15 0.05 blood insulin amount (VT:0001560) plasma insulin level (CMO:0000342) 18 1 38753381 Rat 2312598 Bp340 Blood pressure QTL 340 0.05 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 18 3719547 32487870 Rat 2299160 Iddm35 Insulin dependent diabetes mellitus QTL 35 2.79 blood glucose amount (VT:0000188) age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140) 18 4407513 62570466 Rat 2312568 Glom21 Glomerulus QTL 21 2 0.005 kidney glomerulus morphology trait (VT:0005325) index of glomerular damage (CMO:0001135) 18 5430134 41781619 Rat 2313082 Bss85 Bone structure and strength QTL 85 0.8 0.0001 long bone metaphysis morphology trait (VT:0000133) tibia midshaft total cross-sectional area (CMO:0001715) 18 14678852 59678852 Rat 631264 Scl22 Serum cholesterol level QTL 22 6.2 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 18 15532963 32704022 Rat 61382 Bp46 Blood pressure QTL 46 18.8 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 18 15532963 32704022 Rat 1331766 Bp236 Blood pressure QTL 236 3.022 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 18 15539427 32670473 Rat 1331753 Bp231 Blood pressure QTL 231 3.643 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 18 15539427 53861431 Rat 1358358 Sradr6 Stress Responsive Adrenal Weight QTL 6 2.49 adrenal gland mass (VT:0010420) both adrenal glands wet weight (CMO:0000164) 18 15539427 61499684 Rat 61375 Bp41 Blood pressure QTL 41 2.4 blood pressure trait (VT:0000183) systolic blood pressure (CMO:0000004) 18 15539671 29530300 Rat 6903359 Bp355 Blood pressure QTL 355 3.6 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 18 15539671 61985648 Rat 2293708 Bss46 Bone structure and strength QTL 46 8.8 0.0001 lumbar vertebra morphology trait (VT:0010494) lumbar vertebra cortical cross-sectional area (CMO:0001690) 18 15695872 68524999 Rat 1578661 Bss20 Bone structure and strength QTL 20 3.7 femur morphology trait (VT:0000559) femoral neck cross-sectional area (CMO:0001697) 18 15695872 87080053 Rat 1578667 Bss21 Bone structure and strength QTL 21 3.5 femur morphology trait (VT:0000559) femoral neck cortical cross-sectional area (CMO:0001702) 18 15695872 87080053 Rat 1358193 Emca2 Estrogen-induced mammary cancer QTL 2 1.6 mammary gland integrity trait (VT:0010552) post-insult time to mammary tumor formation (CMO:0000345) 18 19031030 68436105 Rat 1331775 Bp235 Blood pressure QTL 235 3.201 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 18 19251717 32670473 Rat 1331735 Rf44 Renal function QTL 44 2.981 total urine protein amount (VT:0000032) urine total protein excretion rate (CMO:0000756) 18 19251717 32670473 Rat 1600373 Mamtr6 Mammary tumor resistance QTL 6 mammary gland integrity trait (VT:0010552) mammary tumor number (CMO:0000343) 18 20285758 87080053 Rat 7387267 Uae42 Urinary albumin excretion QTL 42 0.61 urine albumin amount (VT:0002871) urine albumin excretion rate (CMO:0000757) 14 21639491 66639491 Rat 1331741 Bp232 Blood pressure QTL 232 3.59112 arterial blood pressure trait (VT:2000000) diastolic blood pressure (CMO:0000005) 18 22603736 87074531 Rat 6903353 Bp353 Blood pressure QTL 353 2.8 arterial blood pressure trait (VT:2000000) diastolic blood pressure (CMO:0000005) 18 22604764 61985648 Rat 1641923 Colcr8 Colorectal carcinoma resistance QTL 8 3.1 0.0014 intestine integrity trait (VT:0010554) poorly differentiated malignant colorectal tumor number (CMO:0002076) 18 23184227 53861431 Rat 1331733 Bp233 Blood pressure QTL 233 3.97196 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 18 25961026 81761656 Rat 2325839 Bp348 Blood pressure QTL 348 0.001 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 18 26743404 43659626 Rat 2301413 Bp318 Blood pressure QTL 318 0.002 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 18 27743024 48499517 Rat 12904673 Cm127 Cardiac mass QTL 127 0.005 heart right ventricle mass (VT:0007033) heart right ventricle weight to body weight ratio (CMO:0000914) 18 27743024 48499517 Rat 12904675 Am19 Aortic mass QTL 19 0.001 aorta mass (VT:0002845) aorta weight to aorta length to body weight ratio (CMO:0002722) 18 27743024 48499517 Rat 12904677 Kidm72 Kidney mass QTL 72 0.001 kidney mass (VT:0002707) both kidneys wet weight to body weight ratio (CMO:0000340) 18 27743024 48499517 Rat 12904668 Bw188 Body weight QTL 188 0.03 body mass (VT:0001259) body weight (CMO:0000012) 18 27743024 48499517 Rat 12904669 Cm125 Cardiac mass QTL 125 0.001 heart mass (VT:0007028) heart wet weight to body weight ratio (CMO:0002408) 18 27743024 48499517 Rat 12904670 Cm126 Cardiac mass QTL 126 0.001 heart left ventricle mass (VT:0007031) heart left ventricle weight to body weight ratio (CMO:0000530) 18 27743024 48499517 Rat